

**Marcela Horvitz-Lennon, MD, MPH**  
**RAND Corporation**  
**20 Park Plaza Suite 920**  
**Boston, MA 02116**  
**Phone: 617-338-2059 x8657**  
**Email: [mhorvitz@rand.org](mailto:mhorvitz@rand.org)**

### **Education**

**Johns Hopkins University**, Baltimore, MD

Masters in Public Health, 1993

**Johns Hopkins University Medical School**, Baltimore, MD

Community Psychiatry Fellowship, 1992-1994

**University of Maryland Medical School**, Baltimore, Maryland

Adult Psychiatry Residency Training, 1988-1992

**Catholic University Medical School**, Santiago, Chile

Doctor of Medicine, 1987

### **Awards and Honors**

Scholars in Medicine Fellowship, Harvard Medical School, 2003

Brody Psychotherapy Award, University of Maryland Medical School, 1992

Stelios M. Stelson Fellowship, Columbus Foundation, 1992

Full Scholarship, Catholic University Medical School, 1982-1984

### **Experience**

**RAND Corporation** (2010-present). Senior Natural Scientist.

**Pardee RAND Graduate School** (2014-present). Core Faculty.

**Cambridge Health Alliance, Department of Psychiatry** (2015-present). Attending psychiatrist and Health Equity Research Lab Senior Scientist

**Harvard Medical School** (2019—present). Associate Professor (Part-Time)

**University of Pittsburgh Medical School, Department of Psychiatry** (2004-2010). Assistant Professor

**Harvard Medical School, Department of Psychiatry** (1997-2004). Instructor in Psychiatry

**Harvard Medical School, Department of Health Care Policy** (2001-2004). Lecturer

**Dept. of Mental Health, Ministry of Health of Chile** (1994-1997). Ministry Official

### **Publications**

Levav I, Lima BR, **Horvitz-Lennon M**, Kramer M, Gonzalez R. Mental health for all in Latin America and the Caribbean. Epidemiologic bases for action. Boletin de la Oficina Sanitaria Panamericana (OPS/PAHO) 1989;107(3):196-219.

Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, **Horvitz-Lennon M**, Frances M. Rating of Medication Influences (ROMI) Scale in schizophrenia. Schizophrenia Bulletin 1994;20(2):297-310.

**Horvitz-Lennon M**, Normand SLT, Gaccione P, Frank RG. Partial versus full hospitalization for adults in psychiatric distress: A systematic review of the published literature (1957-1997). *American Journal of Psychiatry* 2001;158(5):676-85.

**Horvitz-Lennon M**, Normand SLT, Frank RG, Goldman HH. Usual care for major depression in the 1990's: Characteristics and expert-estimated outcomes. *American Journal of Psychiatry* 2003;160(4):720-6.

Tchernis R, **Horvitz-Lennon M**, Normand SLT. On the use of discrete choice models for causal inference. *Statistics in Medicine* 2005;24(14):2197-212.

**Horvitz-Lennon M**, O'Malley J, Frank RG, Normand SLT. Improving traditional intention-to-treat analyses: A new approach. *Psychological Medicine*, 2005;35(7):961-70.

Timbie J, Frank RG, **Horvitz-Lennon M**, Normand SLT. A meta-analysis of labor supply effects of interventions for major depressive disorder. *Psychiatric Services* 2006;57(2):212-8.

**Horvitz-Lennon M**, Kilbourne AK, Pincus HA. From silos to bridges: Meeting the general health care needs of adults with severe mental illnesses. *Health Affairs* 2006;25(3):659-69.

Kilbourne AM, **Horvitz-Lennon M**, Post EP, McCarthy JF, Cruz M, Welsh D, Blow F. Oral health in veterans diagnosed with serious mental illness. *Journal of Public Health Dentistry* 2007;67(1):42-8.

Stuart EA, Marcus SM, **Horvitz-Lennon M**, Gibbons RD, Normand SLT. Using non-experimental data to estimate treatment effects. *Psychiatric Annals* 2009

Lewis-Fernandez R, **Horvitz-Lennon M**, Blanco C, Guarnaccia PJ, Cao Z, Alegria M. Significance of endorsement of psychotic symptoms by US Latinos. *Journal of Nervous and Mental Disorders* 2009;197(5):337-47.

**Horvitz-Lennon M**, Donohue JM, Domino M, Normand SLT. Improving quality and diffusing best practices: The case of schizophrenia. *Health Affairs* 2009;28(3):701-12.

**Horvitz-Lennon M**, McGuire T, Alegria M, Frank RG. Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia. *Health Services Research* 2009;44(6):2106-22.

**Horvitz-Lennon M**, Reynolds S, Wolbert R, Witheridge TF. The role of Assertive Community Treatment in the treatment of persons with borderline personality disorder. *American Journal of Psychiatric Rehabilitation* 2009;12(3):261-77.

**Horvitz-Lennon M**, Frank RG, Thompson W, Baik SH, Alegria M, Rosenheck RA, Normand SLT. Investigation of racial and ethnic disparities in service utilization among homeless adults with severe mental illnesses. *Psychiatric Services* 2009;60(8):1032-8.

**Horvitz-Lennon M**, Watkins KE, Pincus HA, Shugarman LR, Smith B, Mattox T, Mannle TE. *Veteran's Health Administration Mental Health Program Evaluation Technical Manual*. Santa Monica, CA: RAND Corporation. 2009 [http://www.rand.org/pubs/working\\_papers/WR682](http://www.rand.org/pubs/working_papers/WR682).

Watkins KW, Keyser DJ, Smith B, Mannle T, Kivlahan DR, Paddock S, Mattox T, **Horvitz-Lennon M**, Pincus HA. Transforming mental healthcare in the Veterans Health Administration: A model for measuring performance to improve access, quality, and outcomes. *Journal for Healthcare Quality* 2010;32(6):33-42.

Caldas de Almeida JM, **Horvitz-Lennon M**. An overview of mental health care reforms in Latin America and the Caribbean. *Psychiatric Services* 2010;61(3):218-21.

Mulvaney-Day NE, **Horvitz-Lennon M**, Chen C-n, Laderman M, Alegria M. Valuing health in a racially and ethnically diverse community sample: An analysis using the valuation metrics of money and time. *Quality of Life Research* 2010;19(10):1529-40.

Watkins KW, **Horvitz-Lennon, M**, Caldarone L, Shugarman L, Smith B, Mannle T, Kivlahan DR, Pincus HA. Developing medical record-based performance indicators to measure the quality of mental health care. *Journal for Healthcare Quality* 2011;33(1):49-67.

**Horvitz-Lennon M**, Zhou D, Normand SLT, Alegria M, Thompson, W. Racial and ethnic service disparities among homeless adults with severe mental illnesses receiving Assertive Community Treatment. *Psychiatric Services* 2011;62(6):598-604.

Watkins KE, Pincus H A, Paddock S, Smith B, Woodroffe A, Farmer C, Sorbero ME, **Horvitz-Lennon M**, Mannle T Jr, Hepner KA, Solomon J, Call C. Care for veterans with mental and substance use disorders: Good performance, but room to improve on many measures. *Health Affairs* 2011;30(11):2194-203.

Minoletti A, Sepulveda R, **Horvitz-Lennon M**. Twenty years of mental health policies in Chile: Lessons and challenges. *International Journal of Mental Health* 2012;41(1):21-37.

Goldman HH, **Horvitz-Lennon M**, Hu T-W, Alegria M, Chisholm DH, Heinze G, Njenga FG, Regier DA, Sayce L. The economic consequences of revising the diagnostic nomenclature for mental disorders. In: Shekhar S, Esparza P, Regier DA, Saraceno B, editors. *Public Health Aspects of Diagnosis and Classification of Mental and Behavioral Disorders: Refining the Research Agenda for DSM-5 and ICD-11*. American Psychiatric Pub, 2012 p. 125-41.

Minoletti A, Rojas G, **Horvitz-Lennon M**. Integrating mental health into primary care: Lessons from the experience of Chile. In: Sorel E, editor. *21st Century Global Mental Health*. Washington, DC: Jones & Bartlett Publishers, 2012 p. 255-81.

**Horvitz-Lennon M**, Alegria M, Normand, SLT. The effect of race-ethnicity and geography on the adoption of innovations in the treatment of schizophrenia. *Psychiatric Services* 2012;63(12):1171-7.

**Horvitz-Lennon M**, Iyer N, Minoletti A. Do low and middle-income countries learn from the experience of high-income countries? Lessons from the use of atypical antipsychotics for the treatment of schizophrenia. *International Journal of Mental Health* 2013;42(1):33-50.

**Horvitz-Lennon M**, Donohue JM, Lave J, Alegria M, Normand SLT. The effect of race-ethnicity on clozapine outcomes among Medicaid beneficiaries with schizophrenia. *Psychiatric Services* 2013;64(3):230-7.

Pollitt A., Diepeveen S, Guthrie S, **Horvitz-Lennon M**, Jones MM, Ni Chonail S, Schultz DJ, Pincus HA, Grant J, Wooding S. *Mental Health Retrosight: Perspectives*. Santa Monica, CA: RAND. 2013.

Wooding S, Pollitt A, Castle-Clarke S, Cochran G, Diepeveen S, Guthrie S, **Horvitz-Lennon M**, Larivière V, Jones MM, Ni Chonail S, O'Brien C, Olmsted SS, Schultz DJ, Winpenny E, Pincus HA, Grant J. *Mental Health Retrosight: Identifying the attributes of successfully translated research (lessons from schizophrenia)*. Santa Monica, CA: RAND. 2013

Wooding S, Pollitt A, Castle-Clarke S, Cochrane G, Diepeveen S, Guthrie S, **Horvitz-Lennon M**, Larivière V, Jones MM, Ni Chonail S, O'Brien C, Olmsted SS, Schultz DJ, Winpenny E, Pincus HA, Grant J. *Mental Health Retrosight: Understanding the returns from research (lessons from schizophrenia): Policy Report*. Santa Monica, CA: RAND. 2013.

**Horvitz-Lennon M.** The enduring mismatch between service need and use (editorial). *Psychiatric Services* 2013;64(11):1073.

Huskamp H, O'Malley JD, **Horvitz-Lennon M**, Taub AL, Berndt ER, Donohue JM. How quickly do physicians adopt new drugs? The case of antipsychotics. *Psychiatric Services* 2013;64(4):324-30.

Donohue J, O'Malley JD, **Horvitz-Lennon M**, Taub AL, Berndt ER, Huskamp HA. Changes in physician antipsychotic prescribing preferences, 2002–2007. *Psychiatric Services* 2014;65(3):315–22.

**Horvitz-Lennon M**, Volya R, Donohue JM, Lave JR, Stein B, Normand SLT. Disparities in quality of care among publicly insured adults with schizophrenia in four large US states, 2002-2008. *Health Services Research* 2014;49(4):1121-44.

**Horvitz-Lennon M.** Reply (Cohen D: Prescribers fear as a major side-effect of clozapine). *Acta Psychiatrica Scandinavica* 2014;130(2):156.

Scharf DM, Eberhart NK, Hackbarth NS, **Horvitz-Lennon M**, Beckman RL, Han B, Lovejoy SL, Pincus HA, and Burnam MA. Improving the physical health of adults with serious mental illness. Santa Monica, CA: RAND. 2014.

Scharf, D.M., N.K. Eberhart, N.S. Hackbarth, **Horvitz-Lennon M**, Beckman RL, Han B, Lovejoy SL, Pincus HA, Burnam MA. Evaluation of the SAMHSA Primary and Behavioral Health Care Integration (PBHCI) grant program: Final report (Task 13). Santa Monica, CA: RAND. 2014.

**Horvitz-Lennon M**, Breslau J, Scharf D, Doyle MB, Nanda N, Kusuke D, Timbie JW, Kotzias V. Case Study: Early assessment of the Mental Health Block Grant Set-Aside Program for Addressing First Episode Psychosis and other Early Serious Mental Illness: Report prepared under agreement #AMH14001 between the U.S. Department of Health and Human Services (HHS), Office of Disability, Aging and Long-Term Care Policy (DALTCP) and the National Institute of Mental Health. September 2015.

Anderson TS, Huskamp HA, Epstein AJ, Barry CL, Men A, Berndt ER, **Horvitz-Lennon M**, Normand SLT, Donohue JM. Antipsychotic prescribing: Do conflict of interest policies make a difference? *Medical Care* 2015;53(4):338-45.

Predmore ZS, Mattke S, **Horvitz-Lennon M**. Improving antipsychotic adherence among patients with schizophrenia: Savings for states. *Psychiatric Services* 2015;66(4):343-5.

**Horvitz-Lennon M**, Volya R, Garfield R, Donohue JM, Lave JR, Normand SLT. Where you live matters: Quality and racial/ethnic disparities in the care of schizophrenia in four state Medicaid programs. *Health Services Research* 2015;50(5):1710-29.

**Horvitz-Lennon M**, Braun D, Normand, SLT. Challenges in the use of administrative data for heart failure services research. *Journal of Cardiac Failure* 2016;22(1):61.

Donohue JM, Normand SL, **Horvitz-Lennon M**, Men A, Berndt ER and Huskamp HA. Regional Variation in Physician Adoption of Antipsychotics: Impact on US Medicare Expenditures. *J Ment Health Policy Econ* 2016;19(2):69-78.

Reus, VI, Fochtmann LJ, Eyler AE, Hilty DM, **Horvitz-Lennon M**, Jibson MD, Lopez OL, Mahoney J, Pasic J, Tan ZS. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. *American Journal of Psychiatry*; 2016. 173(5):543-546.

Scharf DM, Schmidt Hackbarth N, Eberhart NK, **Horvitz-Lennon M**, Beckman R, Han B, Pincus HA and Burnam MA. General medical outcomes from the Primary and Behavioral Health Care Integration grant program. *Psychiatric Services* 2016;67(11):1226-1232.

Huskamp HA, **Horvitz-Lennon M**, Berndt ER, Normand ST and Donohue JM. Patterns of Antipsychotic Prescribing by Physicians to Young Children. *Psychiatr Serv* 2016;67(12):1307-1314.

**Horvitz-Lennon M**, Mattke S, Predmore Z and Howes OD. The Role of Antipsychotic Plasma Levels in the Treatment of Schizophrenia. *American Journal of Psychiatry* 2017;174(5):421-426.

Breslau J, Yu H, **Horvitz-Lennon M**, Leckman-Westin E, Scharf DM, Connor KL and Finnerty MT. Enrollment of Specialty Mental Health Clinics in a State Medicaid Program to Promote General Medical Services. *Psychiatr Serv* 2017;68(1):63-69.

Tang Y, **Horvitz-Lennon M**, Gellad WF, Lave JR, Chang C-CH, Normand S-L and Donohue JM. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program. *Psychiatric Services* 2017;68(6):579-586.

Mulcahy AW, Normand S-L, Newcomer JW, Colaiaco B, Donohue JM, Lave JR, Keeler E, Sorbero MJ and **Horvitz-Lennon M**. Simulated Effects of Policies to Reduce Diabetes Risk Among Adults with Schizophrenia Receiving Antipsychotics. *Psychiatric Services* 2017;68(12):1280-1287.

Predmore Z, Mattke S and **Horvitz-Lennon M**. Potential Benefits to Patients and Payers From Increased Measurement of Antipsychotic Plasma Levels in the Management of Schizophrenia. *Psychiatr Serv* 2018;69(1):12-14.

Spertus J, **Horvitz-Lennon M**, Abing H and Normand S-L. Risk of weight gain for specific antipsychotic drugs: a meta-analysis. *NPJ Schizophrenia* 2018;4(1):12.

Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, **Horvitz-Lennon M**, Mahoney J, Pasic J, Weaver M, Wills CD, McIntyre J, Kidd J, Yager J, Hong SH. The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. *American Journal of Psychiatry*; 2018. 175(1):86-90.

Breslau J, Leckman-Westin E, Yu H, Han B, Pritam R, Guarasi D, **Horvitz-Lennon M**, Scharf DM, Pincus HA and Finnerty MT. Impact of a mental health based primary care program on quality of physical health care. *Administration and Policy in Mental Health and Mental Health Services Research* 2018;45(2):276-285.

Breslau J, Leckman-Westin E, Han B, Pritam R, Guarasi D, **Horvitz-Lennon M**, Scharf DM, Finnerty MT and Yu H. Impact of a mental health based primary care program on emergency department visits and inpatient stays. *General Hospital Psychiatry* 2018;52:8-13.

Gopalan K, **Horvitz-Lennon M**, Stein BD, Ghinassi F, Castle N, Chang J and Donohue J. Is Mental Illness a Risk Factor for Hospital Readmission? *Administration and Policy in Mental Health and Mental Health Services Research* 2018.

Breslau J, Elliott MN, Haviland AM, Klein DJ, Dembosky JW, Adams JL, Gaillot SJ, **Horvitz-Lennon M** and Schneider EC. Racial And Ethnic Differences In The Attainment Of Behavioral Health Quality Measures In Medicare Advantage Plans. *Health Affairs* 2018;37(10):1685-1692.

**Horvitz-Lennon M**, Predmore Z, Orr P, Hanson M, Hillestad R, Durkin M, Kim E and Mattke S. Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia. *Early Interv Psychiatry* 2019;13(6):1357-1365.

Breslau J, Pritam R, Guarasi D, **Horvitz-Lennon M**, Finnerty M, Yu H and Leckman-Westin E. Predictors of Receipt of Physical Health Services in Mental Health Clinics. *Community Ment Health J* 2019;55(8):1279-1287.

Spertus J, **Horvitz-Lennon M** and Normand ST. Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs. *Med Decis Making* 2019;39(5):583-592.

**Horvitz-Lennon M**, Predmore Z, Orr P, Hanson M, Hillestad R, Durkin M, El Khoury AC and Mattke S. The Predicted Long-Term Benefits of Ensuring Timely Treatment and Medication Adherence in Early Schizophrenia. *Adm Policy Ment Health* 2019.

**Horvitz-Lennon M**. Evidence-Based Practices or Practice-Based Evidence: What Is The Future? In: Goldman H, Frank R, and Morrissey J, editors. *The Palgrave Handbook of American Mental Health Policy*. Palgrave Macmillan, 2020 p. 603-638.

### **Presentations (selected)**

- 2010        “Racial and Ethnic Disparities in the Treatment of a Medicaid Population with Schizophrenia”/Invited Lecture  
National Hispanic Science Network 2010 International Conference  
New Orleans, LA
- 2010        “Racial and Ethnic Disparities in the Treatment of a Medicaid Population with Schizophrenia”/Invited Lecture  
National Hispanic Science Network 2010 International Conference  
New Orleans, LA
- 2011        “The Effect of Race/Ethnicity and Geography on Adoption of a Novel Antipsychotic Medication among Publicly Insured Adults with Schizophrenia”  
Mental Health Service Disparities, from Disparities Research to Disparities Interventions Annual Conference: Lessons Learned and Opportunities for the Future of Behavioral Health Services  
Arlington, VA
- 2014        “Policy Lessons Learned from Health Administrative Datasets: Improving Mental Health Care”/Invited Lecture  
CUTEHeart Workshop (“Health Services Research: From Data to Practice”)  
Lisbon, Portugal
- 2015        “Use of clozapine and antipsychotic polypharmacy among patients with schizophrenia: Characterizing the prescribers”/Abstract Presentation  
ISPOR 20<sup>th</sup> Annual International Meeting  
Philadelphia, PA, USA
- 2016        “Point of Care Antipsychotic Plasma Levels for Patients with Schizophrenia: Cost Savings Potential in Spain”/Poster Session  
ISPOR 19th Annual European Congress  
Vienna, Austria
- 2016        “Potential Cost Savings of Having Access to Antipsychotic Plasma Levels at the Point of Care for Patients with Schizophrenia”/Poster Session  
ISPOR 21st Annual International Meeting  
Washington, DC, USA.

- 2018 “The Long-Term Benefits of Ensuring Timely Treatment and Improved Medication Adherence in Early Schizophrenia: A Microsimulation Study”/Poster Session  
ISPOR 23d Annual International Meeting  
Baltimore, MD, USA.
- 2018 “The Effects of Race/Ethnicity and Cardiometabolic Morbidity on Antipsychotic Overuse Among Publicly Insured Adults”/Abstract Presentation (Physical Health Symposium)  
National Institutes of Mental Health 24th Mental Health Services Research Conference  
Bethesda, MD, USA.

**Professional Organizations**

- |                         |                                   |
|-------------------------|-----------------------------------|
| 1990-1994               | Maryland Psychiatric Society      |
| 1990-present            | American Psychiatric Association  |
| 1997-2004, 2015-present | Massachusetts Psychiatric Society |
| 2004-2015               | Pennsylvania Psychiatric Society  |